- Home
- OLMA vs FHTX Comparison
OLMA vs FHTX Comparison
Compare OLMA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- FHTX
- Stock Information
- Founded
- OLMA 2006
- FHTX 2015
- Country
- OLMA United States
- FHTX United States
- Employees
- OLMA N/A
- FHTX N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- OLMA Health Care
- FHTX Health Care
- Exchange
- OLMA Nasdaq
- FHTX Nasdaq
- Market Cap
- OLMA 299.7M
- FHTX 278.1M
- IPO Year
- OLMA 2020
- FHTX 2020
- Fundamental
- Price
- OLMA $5.76
- FHTX $5.56
- Analyst Decision
- OLMA Strong Buy
- FHTX Strong Buy
- Analyst Count
- OLMA 5
- FHTX 6
- Target Price
- OLMA $24.00
- FHTX $11.33
- AVG Volume (30 Days)
- OLMA 532.6K
- FHTX 106.4K
- Earning Date
- OLMA 08-11-2025
- FHTX 08-05-2025
- Dividend Yield
- OLMA N/A
- FHTX N/A
- EPS Growth
- OLMA N/A
- FHTX N/A
- EPS
- OLMA N/A
- FHTX N/A
- Revenue
- OLMA N/A
- FHTX $24,173,000.00
- Revenue This Year
- OLMA N/A
- FHTX $33.60
- Revenue Next Year
- OLMA N/A
- FHTX $5.87
- P/E Ratio
- OLMA N/A
- FHTX N/A
- Revenue Growth
- OLMA N/A
- FHTX N/A
- 52 Week Low
- OLMA $2.86
- FHTX $2.95
- 52 Week High
- OLMA $13.93
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- OLMA 63.92
- FHTX 55.83
- Support Level
- OLMA $5.34
- FHTX $4.75
- Resistance Level
- OLMA $5.78
- FHTX $5.30
- Average True Range (ATR)
- OLMA 0.34
- FHTX 0.35
- MACD
- OLMA 0.05
- FHTX 0.03
- Stochastic Oscillator
- OLMA 85.90
- FHTX 90.04
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.